Please login to the form below

Not currently logged in
Email:
Password:

Vizamyl

This page shows the latest Vizamyl news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • Biosimilar Lantus leads CHMP opinions Biosimilar Lantus leads CHMP opinions

    event. In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease. ... Vizamyl is a biomarker that can detect amyloid-beta neuritic plaques, where are formations in the brain associated with

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    18F) and GE Healthcare's Vizamyl (flutemetamol F18) on the market.

  • FDA approves Alzheimer's diagnostic drug FDA approves Alzheimer's diagnostic drug

    Vizamyl works by attaching to a peptide called beta amyloid in the brain, high levels of which have been associated with the development of Alzheimer's. ... A PET scan can then detect the presence of Vizamyl, allowing physicians to evaluate for the

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics